
Cell Therapy Market. - forecast to 2033 : By CELL TYPE (Stem, T-cell Therapy, Dendritic, Natural Killer, Mesenchymal Stem Cell, Induced Pluripotent Stem Cell), THERAPEUTIC AREA (Oncology, Cardiovascular Disorders, Neurological Disorders, Musculoskeletal D
Description
Cell Therapy Market. - forecast to 2033 : By CELL TYPE (Stem, T-cell Therapy, Dendritic, Natural Killer, Mesenchymal Stem Cell, Induced Pluripotent Stem Cell), THERAPEUTIC AREA (Oncology, Cardiovascular Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune Disorders, Dermatological Disorders, Others), APPLICATION (Regenerative Medicine, Tissue Engineering, Immunotherapy, Gene Therapy, Cell-based Assays, Others), END-USER (Hospitals & Clinics, Research Institutes, Biotechnology, Pharmaceutical Companies), STAGE OF DEVELOPMENT (Preclinical, Phase I, Phase II, Phase III, Commercialized), TECHNOLOGY (Viral Vector-based, Non-viral Vector-based, Gene Editing Technologies), MODE OF DELIVERY (Intravenous, Intramuscular, Subcutaneous, Others), and Region
The cell therapy market represents a cutting-edge segment of the biopharmaceutical industry, focused on the treatment of diseases by altering cellular function or replacing damaged or diseased cells with healthy ones. This market includes a variety of therapies, such as immunotherapy with T-cells, stem cell therapies, and gene editing technologies. These therapies are designed to address a wide range of conditions, from cancers and autoimmune diseases to inherited metabolic disorders and beyond. The Cell Therapy Market size was USD 4.3 Billion in 2023, and it is anticipated to grow to over 11.2 Billion by 2033, at a CAGR of over 11.6% during the forecast period.
A key factor propelling the cell therapy market is the significant investment in research and development, which has led to breakthroughs in regenerative medicine and an increasing number of cell therapy products advancing through clinical trials. The promise of these therapies to provide potentially curative treatments for previously intractable diseases has garnered substantial interest from both the public and private sectors.
Key Trends:
- Personalized Medicine Advancements: Tailored cell therapy treatments are becoming more prevalent, offering customized healthcare solutions based on individual genetic profiles.
- Regenerative Medicine Growth: A significant increase in the application of cell therapies for regenerating damaged tissues and organs, particularly in orthopedics and wound healing.
- CAR-T Cell Therapies Breakthroughs: Chimeric Antigen Receptor (CAR) T-cell therapies are gaining momentum, especially in the treatment of certain types of cancer, with a focus on enhancing efficacy and reducing side effects.
- Expansion of Stem Cell Research: Stem cell therapies are experiencing a surge in interest for their potential to treat a wide range of diseases, leading to increased investment in research and development.
- Integration of AI and Machine Learning: The use of artificial intelligence and machine learning algorithms to optimize cell therapy development processes, from drug discovery to personalized treatment protocols.
- Innovative Breakthroughs in Regenerative Medicine: Continuous advancements in stem cell research and gene editing technologies are propelling the cell therapy market forward, offering new treatment avenues for various diseases.
- Rising Prevalence of Chronic Diseases: The increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular diseases is driving the demand for cell therapies that offer potentially curative benefits.
- Supportive Regulatory Environment: Regulatory agencies are providing expedited pathways for cell therapies that address unmet medical needs, thereby accelerating the development and approval process.
- Expansion of Manufacturing Capabilities: Advances in bioprocessing and automation are enhancing the scalability and efficiency of cell therapy production, making treatments more accessible.
- Growing Investment and Collaboration: There is a surge in financial investment from both public and private sectors, coupled with strategic partnerships, which is fueling research, clinical trials, and market entry of new therapies.
- Regulatory Hurdles: Stringent regulations and lengthy approval processes for new cell therapies pose significant challenges, often delaying market entry and increasing development costs.
- Ethical and Social Concerns: Ethical debates and public apprehension regarding the use of stem cells, particularly embryonic stem cells, can hinder research funding and acceptance of cell therapy treatments.
- High Treatment Costs: The complex manufacturing and handling of cell therapies result in exorbitant treatment prices, limiting accessibility and adoption across various patient demographics.
- Technical Challenges in Production: Cell therapy products require sophisticated production facilities and processes, which can be difficult to scale, impacting the ability to meet market demand.
- Limited Long-Term Data: As a relatively new field, there is a lack of comprehensive long-term data on the efficacy and safety of cell therapies, which can affect physician endorsement and patient trust.
Cell Type (Stem, T-cell Therapy, Dendritic, Natural Killer, Mesenchymal Stem Cell, Induced Pluripotent Stem Cell), Therapeutic Area (Oncology, Cardiovascular Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune Disorders, Dermatological Disorders, Others), Application (Regenerative Medicine, Tissue Engineering, Immunotherapy, Gene Therapy, Cell-based Assays, Others), End-User (Hospitals & Clinics, Research Institutes, Biotechnology, Pharmaceutical Companies), Stage Of Development (Preclinical, Phase I, Phase II, Phase III, Commercialized), Technology (Viral Vector-based, Non-viral Vector-based, Gene Editing Technologies), Mode Of Delivery (Intravenous, Intramuscular, Subcutaneous, Others), and Region
Key Players:
The Cell Therapy Market includes players such as Gilead Sciences, Novartis, Bristol Myers Squibb, Amgen, Regeneron Pharmaceuticals, Bluebird Bio, CRISPR Therapeutics, Celgene Corporation, Kite Pharma, Juno Therapeutics, Vericel Corporation, Fate Therapeutics, Spark Therapeutics, Humanigen, Poseida Therapeutics, Sangamo Therapeutics, Orchard Therapeutics, Adaptimmune Therapeutics, Nkarta Therapeutics, and Allogene Therapeutics, among others.
Value Chain Analysis:
The value chain analysis for the Cell Therapy Market can be delineated into five critical stages, each contributing uniquely to the overall market dynamics and value creation. These stages include Raw Material Procurement, Research and Development (R&D), Product Approval, Large Scale Manufacturing, and Sales and Marketing. Below is a comprehensive analysis of these stages:
- Raw Material Procurement: Identify sources of raw materials, assess their availability, quality, and sustainability. Understanding market dynamics, pricing trends, and potential risks associated with sourcing materials is crucial. For Cell Therapy, this involves sourcing high-quality biological materials, growth media, and reagents. Ensuring a robust supply chain with reliable suppliers is essential to maintain consistency and quality in the raw materials.
- Research and Development (R&D): R&D focuses on market analysis, trend forecasting, feasibility studies, and conducting experiments to develop new products or enhance existing ones. In the Cell Therapy market, this stage is pivotal for innovation, involving extensive research on cell biology, genetic engineering, and therapeutic applications. Collaboration with academic institutions and leveraging advanced technologies like CRISPR and AI-driven analytics can accelerate the development of cutting-edge therapies.
- Product Approval: Understanding legal requirements, industry regulations, and certification processes, testing products for safety, efficacy, and environmental impact. The Cell Therapy market is heavily regulated, necessitating rigorous clinical trials and compliance with entities such as the FDA, EMA, and other regulatory bodies. This stage involves comprehensive documentation, submission of data, and continuous communication with regulatory authorities to obtain necessary approvals.
- Large Scale Manufacturing: Optimizing production processes, improving efficiency, and reducing costs. Process engineering, automation technologies, and supply chain management to enhance productivity and quality. For Cell Therapy, this stage requires state-of-the-art manufacturing facilities adhering to Good Manufacturing Practices (GMP). Scaling up production from lab to commercial scale while ensuring the integrity and sterility of cell therapies is critical. This may involve bioreactors, automated cell culture systems, and stringent quality control measures.
- Sales and Marketing: Understanding customer needs, market trends, and competitive landscape, market segmentation, consumer behavior analysis, and branding strategies. In the Cell Therapy market, this stage involves educating healthcare providers and patients about the benefits and applications of cell therapies. Strategic partnerships with medical institutions, targeted marketing campaigns, and participation in industry conferences can enhance market penetration. Additionally, leveraging digital marketing and social media platforms can broaden reach and engagement with potential customers.
- Estimates and forecast the overall market size for the total market, across type, application, and region
- Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
- Identify factors influencing market growth and challenges, opportunities, drivers, and restraints
- Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
- Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
- Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
- To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements
- Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
350 Pages
- 1.0: MARKET DEFINITION
- 1.1: MARKET SEGMENTATION
- 1.2: MARKET SEGMENTATION
- 1.3: REGIONAL COVERAGE
- 1.4: KEY COMPANY PROFILES
- 1.5: DATA SNAPSHOT
- 2.0: SUMMARY
- 2.1: SUMMARY
- 2.2: KEY OPINION LEADERS
- 2.3: KEY HIGHLIGHTS BY CELL TYPE
- 2.4: KEY HIGHLIGHTS BY THERAPEUTIC AREA
- 2.5: KEY HIGHLIGHTS BY APPLICATION
- 2.6: KEY HIGHLIGHTS BY END-USER
- 2.7: KEY HIGHLIGHTS BY STAGE OF DEVELOPMENT
- 2.8: KEY HIGHLIGHTS BY TECHNOLOGY
- 2.9: KEY HIGHLIGHTS BY MODE OF DELIVERY
- 2.10: KEY HIGHLIGHTS BY REGION
- 2.11: KEY HIGHLIGHTS BY NORTH AMERICA
- 2.12: KEY HIGHLIGHTS BY LATIN AMERICA
- 2.13: KEY HIGHLIGHTS BY EUROPE
- 2.14: KEY HIGHLIGHTS BY ASIA-PACIFIC
- 2.15: KEY HIGHLIGHTS BY MIDDLE EAST AFRICA
- 3.0: MARKET ATTRACTIVENESS ANALYSIS BY CELL TYPE
- 3.1: MARKET ATTRACTIVENESS ANALYSIS BY THERAPEUTIC AREA
- 3.2: MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
- 3.3: MARKET ATTRACTIVENESS ANALYSIS BY END-USER
- 3.4: MARKET ATTRACTIVENESS ANALYSIS BY STAGE OF DEVELOPMENT
- 3.5: MARKET ATTRACTIVENESS ANALYSIS BY TECHNOLOGY
- 3.6: MARKET ATTRACTIVENESS ANALYSIS BY MODE OF DELIVERY
- 3.7: MARKET ATTRACTIVENESS ANALYSIS BY REGION
- 3.8: MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
- 4.0: MARKET TRENDS
- 4.1: MARKET DRIVERS
- 4.2: MARKET OPPORTUNITIES
- 4.3: MARKET RESTRAINTS
- 4.4: MARKET THREATS
- 4.5: IMPACT ANALYSIS
- 5.0: PORTERS FIVE FORCES
- 5.1: ANSOFF MATRIX
- 5.2: PESTLE ANALYSIS
- 5.3: VALUE CHAIN ANALYSIS
- 6.0: IMPACT OF COVID-19 ON MARKET
- 7.0: IMPACT OF RUSSIA-UKRAINE WAR
- 8.0: PARENT MARKET ANALYSIS
- 8.1: REGULATORY LANDSCAPE
- 8.2: PRICING ANALYSIS
- 8.3: DEMAND SUPPLY ANALYSIS
- 8.4: DEMAND SUPPLY ANALYSIS
- 8.5: CONSUMER BUYING INTEREST
- 8.6: CONSUMER BUYING INTEREST
- 8.7: SUPPLY CHAIN ANALYSIS
- 8.8: COMPETITION PRODUCT ANALYSIS BY MANUFACTURER
- 8.9: TECHNOLOGICAL ADVANCEMENTS
- 8.10: RECENT DEVELOPMENTS
- 8.11: CASE STUDIES
- 9.0: MARKET SIZE AND FORECAST – BY VALUE (US$ MILLION)
- 9.1: MARKET SIZE AND FORECAST – BY VOLUME (UNITS)
- 10.0: CELL TYPE OVERVIEW
- 10.1: MARKET SIZE AND FORECAST – BY CELL TYPE
- 10.2: STEM OVERVIEW
- 10.3: STEM BY REGION
- 10.4: STEM BY COUNTRY
- 10.5: T-CELL THERAPY OVERVIEW
- 10.6: T-CELL THERAPY BY REGION
- 10.7: T-CELL THERAPY BY COUNTRY
- 10.8: DENDRITIC OVERVIEW
- 10.9: DENDRITIC BY REGION
- 10.10: DENDRITIC BY COUNTRY
- 10.11: NATURAL KILLER OVERVIEW
- 10.12: NATURAL KILLER BY REGION
- 10.13: NATURAL KILLER BY COUNTRY
- 10.14: MESENCHYMAL STEM CELL OVERVIEW
- 10.15: MESENCHYMAL STEM CELL BY REGION
- 10.16: MESENCHYMAL STEM CELL BY COUNTRY
- 10.17: INDUCED PLURIPOTENT STEM CELL OVERVIEW
- 10.18: INDUCED PLURIPOTENT STEM CELL BY REGION
- 10.19: INDUCED PLURIPOTENT STEM CELL BY COUNTRY
- 11.0: THERAPEUTIC AREA OVERVIEW
- 11.1: MARKET SIZE AND FORECAST – BY THERAPEUTIC AREA
- 11.2: ONCOLOGY OVERVIEW
- 11.3: ONCOLOGY BY REGION
- 11.4: ONCOLOGY BY COUNTRY
- 11.5: CARDIOVASCULAR DISORDERS OVERVIEW
- 11.6: CARDIOVASCULAR DISORDERS BY REGION
- 11.7: CARDIOVASCULAR DISORDERS BY COUNTRY
- 11.8: NEUROLOGICAL DISORDERS OVERVIEW
- 11.9: NEUROLOGICAL DISORDERS BY REGION
- 11.10: NEUROLOGICAL DISORDERS BY COUNTRY
- 11.11: MUSCULOSKELETAL DISORDERS OVERVIEW
- 11.12: MUSCULOSKELETAL DISORDERS BY REGION
- 11.13: MUSCULOSKELETAL DISORDERS BY COUNTRY
- 11.14: AUTOIMMUNE DISORDERS OVERVIEW
- 11.15: AUTOIMMUNE DISORDERS BY REGION
- 11.16: AUTOIMMUNE DISORDERS BY COUNTRY
- 11.17: DERMATOLOGICAL DISORDERS OVERVIEW
- 11.18: DERMATOLOGICAL DISORDERS BY REGION
- 11.19: DERMATOLOGICAL DISORDERS BY COUNTRY
- 11.20: OTHERS OVERVIEW
- 11.21: OTHERS BY REGION
- 11.22: OTHERS BY COUNTRY
- 12.0: APPLICATION OVERVIEW
- 12.1: MARKET SIZE AND FORECAST – BY APPLICATION
- 12.2: REGENERATIVE MEDICINE OVERVIEW
- 12.3: REGENERATIVE MEDICINE BY REGION
- 12.4: REGENERATIVE MEDICINE BY COUNTRY
- 12.5: TISSUE ENGINEERING OVERVIEW
- 12.6: TISSUE ENGINEERING BY REGION
- 12.7: TISSUE ENGINEERING BY COUNTRY
- 12.8: IMMUNOTHERAPY OVERVIEW
- 12.9: IMMUNOTHERAPY BY REGION
- 12.10: IMMUNOTHERAPY BY COUNTRY
- 12.11: GENE THERAPY OVERVIEW
- 12.12: GENE THERAPY BY REGION
- 12.13: GENE THERAPY BY COUNTRY
- 12.14: CELL-BASED ASSAYS OVERVIEW
- 12.15: CELL-BASED ASSAYS BY REGION
- 12.16: CELL-BASED ASSAYS BY COUNTRY
- 12.17: OTHERS OVERVIEW
- 12.18: OTHERS BY REGION
- 12.19: OTHERS BY COUNTRY
- 13.0: END-USER OVERVIEW
- 13.1: MARKET SIZE AND FORECAST – BY END-USER
- 13.2: HOSPITALS & CLINICS OVERVIEW
- 13.3: HOSPITALS & CLINICS BY REGION
- 13.4: HOSPITALS & CLINICS BY COUNTRY
- 13.5: RESEARCH INSTITUTES OVERVIEW
- 13.6: RESEARCH INSTITUTES BY REGION
- 13.7: RESEARCH INSTITUTES BY COUNTRY
- 13.8: BIOTECHNOLOGY OVERVIEW
- 13.9: BIOTECHNOLOGY BY REGION
- 13.10: BIOTECHNOLOGY BY COUNTRY
- 13.11: PHARMACEUTICAL COMPANIES OVERVIEW
- 13.12: PHARMACEUTICAL COMPANIES BY REGION
- 13.13: PHARMACEUTICAL COMPANIES BY COUNTRY
- 14.0: STAGE OF DEVELOPMENT OVERVIEW
- 14.1: MARKET SIZE AND FORECAST – BY STAGE OF DEVELOPMENT
- 14.2: PRECLINICAL OVERVIEW
- 14.3: PRECLINICAL BY REGION
- 14.4: PRECLINICAL BY COUNTRY
- 14.5: PHASE I OVERVIEW
- 14.6: PHASE I BY REGION
- 14.7: PHASE I BY COUNTRY
- 14.8: PHASE II OVERVIEW
- 14.9: PHASE II BY REGION
- 14.10: PHASE II BY COUNTRY
- 14.11: PHASE III OVERVIEW
- 14.12: PHASE III BY REGION
- 14.13: PHASE III BY COUNTRY
- 14.14: COMMERCIALIZED OVERVIEW
- 14.15: COMMERCIALIZED BY REGION
- 14.16: COMMERCIALIZED BY COUNTRY
- 15.0: TECHNOLOGY OVERVIEW
- 15.1: MARKET SIZE AND FORECAST – BY TECHNOLOGY
- 15.2: VIRAL VECTOR-BASED OVERVIEW
- 15.3: VIRAL VECTOR-BASED BY REGION
- 15.4: VIRAL VECTOR-BASED BY COUNTRY
- 15.5: NON-VIRAL VECTOR-BASED OVERVIEW
- 15.6: NON-VIRAL VECTOR-BASED BY REGION
- 15.7: NON-VIRAL VECTOR-BASED BY COUNTRY
- 15.8: GENE EDITING TECHNOLOGIES OVERVIEW
- 15.9: GENE EDITING TECHNOLOGIES BY REGION
- 15.10: GENE EDITING TECHNOLOGIES BY COUNTRY
- 16.0: MODE OF DELIVERY OVERVIEW
- 16.1: MARKET SIZE AND FORECAST – BY MODE OF DELIVERY
- 16.2: INTRAVENOUS OVERVIEW
- 16.3: INTRAVENOUS BY REGION
- 16.4: INTRAVENOUS BY COUNTRY
- 16.5: INTRAMUSCULAR OVERVIEW
- 16.6: INTRAMUSCULAR BY REGION
- 16.7: INTRAMUSCULAR BY COUNTRY
- 16.8: SUBCUTANEOUS OVERVIEW
- 16.9: SUBCUTANEOUS BY REGION
- 16.10: SUBCUTANEOUS BY COUNTRY
- 16.11: OTHERS OVERVIEW
- 16.12: OTHERS BY REGION
- 16.13: OTHERS BY COUNTRY
- 17.0: REGION OVERVIEW
- 17.1: MARKET SIZE AND FORECAST - BY REGION
- 17.2: NORTH AMERICA OVERVIEW
- 17.3: NORTH AMERICA BY COUNTRY
- 17.4: UNITED STATES OVERVIEW
- 17.5: UNITED STATES OVERVIEW
- 17.6: UNITED STATES OVERVIEW
- 17.7: UNITED STATES OVERVIEW
- 17.8: UNITED STATES OVERVIEW
- 17.9: UNITED STATES OVERVIEW
- 17.10: UNITED STATES OVERVIEW
- 17.11: UNITED STATES OVERVIEW
- 17.12: LOCAL MARKET ANALYSIS - UNITED STATES
- 17.13: COMPETITIVE ANALYSIS - UNITED STATES
- 17.14: CANADA OVERVIEW
- 17.15: CANADA OVERVIEW
- 17.16: CANADA OVERVIEW
- 17.17: CANADA OVERVIEW
- 17.18: CANADA OVERVIEW
- 17.19: CANADA OVERVIEW
- 17.20: CANADA OVERVIEW
- 17.21: CANADA OVERVIEW
- 17.22: LOCAL MARKET ANALYSIS - CANADA
- 17.23: COMPETITIVE ANALYSIS - CANADA
- 17.24: LATIN AMERICA OVERVIEW
- 17.25: LATIN AMERICA BY COUNTRY
- 17.26: MEXICO OVERVIEW
- 17.27: MEXICO OVERVIEW
- 17.28: MEXICO OVERVIEW
- 17.29: MEXICO OVERVIEW
- 17.30: MEXICO OVERVIEW
- 17.31: MEXICO OVERVIEW
- 17.32: MEXICO OVERVIEW
- 17.33: MEXICO OVERVIEW
- 17.34: LOCAL MARKET ANALYSIS - MEXICO
- 17.35: COMPETITIVE ANALYSIS - MEXICO
- 17.36: BRAZIL OVERVIEW
- 17.37: BRAZIL OVERVIEW
- 17.38: BRAZIL OVERVIEW
- 17.39: BRAZIL OVERVIEW
- 17.40: BRAZIL OVERVIEW
- 17.41: BRAZIL OVERVIEW
- 17.42: BRAZIL OVERVIEW
- 17.43: BRAZIL OVERVIEW
- 17.44: LOCAL MARKET ANALYSIS - BRAZIL
- 17.45: COMPETITIVE ANALYSIS - BRAZIL
- 17.46: ARGENTINA OVERVIEW
- 17.47: ARGENTINA OVERVIEW
- 17.48: ARGENTINA OVERVIEW
- 17.49: ARGENTINA OVERVIEW
- 17.50: ARGENTINA OVERVIEW
- 17.51: ARGENTINA OVERVIEW
- 17.52: ARGENTINA OVERVIEW
- 17.53: ARGENTINA OVERVIEW
- 17.54: LOCAL MARKET ANALYSIS - ARGENTINA
- 17.55: COMPETITIVE ANALYSIS - ARGENTINA
- 17.56: REST OF LATAM OVERVIEW
- 17.57: REST OF LATAM OVERVIEW
- 17.58: REST OF LATAM OVERVIEW
- 17.59: REST OF LATAM OVERVIEW
- 17.60: REST OF LATAM OVERVIEW
- 17.61: REST OF LATAM OVERVIEW
- 17.62: REST OF LATAM OVERVIEW
- 17.63: REST OF LATAM OVERVIEW
- 17.64: LOCAL MARKET ANALYSIS - REST OF LATAM
- 17.65: COMPETITIVE ANALYSIS - REST OF LATAM
- 17.66: EUROPE OVERVIEW
- 17.67: EUROPE BY COUNTRY
- 17.68: GERMANY OVERVIEW
- 17.69: GERMANY OVERVIEW
- 17.70: GERMANY OVERVIEW
- 17.71: GERMANY OVERVIEW
- 17.72: GERMANY OVERVIEW
- 17.73: GERMANY OVERVIEW
- 17.74: GERMANY OVERVIEW
- 17.75: GERMANY OVERVIEW
- 17.76: LOCAL MARKET ANALYSIS - GERMANY
- 17.77: COMPETITIVE ANALYSIS - GERMANY
- 17.78: FRANCE OVERVIEW
- 17.79: FRANCE OVERVIEW
- 17.80: FRANCE OVERVIEW
- 17.81: FRANCE OVERVIEW
- 17.82: FRANCE OVERVIEW
- 17.83: FRANCE OVERVIEW
- 17.84: FRANCE OVERVIEW
- 17.85: FRANCE OVERVIEW
- 17.86: LOCAL MARKET ANALYSIS - FRANCE
- 17.87: COMPETITIVE ANALYSIS - FRANCE
- 17.88: UNITED KINGDOM OVERVIEW
- 17.89: UNITED KINGDOM OVERVIEW
- 17.90: UNITED KINGDOM OVERVIEW
- 17.91: UNITED KINGDOM OVERVIEW
- 17.92: UNITED KINGDOM OVERVIEW
- 17.93: UNITED KINGDOM OVERVIEW
- 17.94: UNITED KINGDOM OVERVIEW
- 17.95: UNITED KINGDOM OVERVIEW
- 17.96: LOCAL MARKET ANALYSIS - UNITED KINGDOM
- 17.97: COMPETITIVE ANALYSIS - UNITED KINGDOM
- 17.98: RUSSIA OVERVIEW
- 17.99: RUSSIA OVERVIEW
- 17.100: RUSSIA OVERVIEW
- 17.101: RUSSIA OVERVIEW
- 17.102: RUSSIA OVERVIEW
- 17.103: RUSSIA OVERVIEW
- 17.104: RUSSIA OVERVIEW
- 17.105: RUSSIA OVERVIEW
- 17.106: LOCAL MARKET ANALYSIS - RUSSIA
- 17.107: COMPETITIVE ANALYSIS - RUSSIA
- 17.108: SPAIN OVERVIEW
- 17.109: SPAIN OVERVIEW
- 17.110: SPAIN OVERVIEW
- 17.111: SPAIN OVERVIEW
- 17.112: SPAIN OVERVIEW
- 17.113: SPAIN OVERVIEW
- 17.114: SPAIN OVERVIEW
- 17.115: SPAIN OVERVIEW
- 17.116: LOCAL MARKET ANALYSIS - SPAIN
- 17.117: COMPETITIVE ANALYSIS - SPAIN
- 17.118: ITALY OVERVIEW
- 17.119: ITALY OVERVIEW
- 17.120: ITALY OVERVIEW
- 17.121: ITALY OVERVIEW
- 17.122: ITALY OVERVIEW
- 17.123: ITALY OVERVIEW
- 17.124: ITALY OVERVIEW
- 17.125: ITALY OVERVIEW
- 17.126: LOCAL MARKET ANALYSIS - ITALY
- 17.127: COMPETITIVE ANALYSIS - ITALY
- 17.128: NETHERLANDS OVERVIEW
- 17.129: NETHERLANDS OVERVIEW
- 17.130: NETHERLANDS OVERVIEW
- 17.131: NETHERLANDS OVERVIEW
- 17.132: NETHERLANDS OVERVIEW
- 17.133: NETHERLANDS OVERVIEW
- 17.134: NETHERLANDS OVERVIEW
- 17.135: NETHERLANDS OVERVIEW
- 17.136: LOCAL MARKET ANALYSIS - NETHERLANDS
- 17.137: COMPETITIVE ANALYSIS - NETHERLANDS
- 17.138: ISRAEL OVERVIEW
- 17.139: ISRAEL OVERVIEW
- 17.140: ISRAEL OVERVIEW
- 17.141: ISRAEL OVERVIEW
- 17.142: ISRAEL OVERVIEW
- 17.143: ISRAEL OVERVIEW
- 17.144: ISRAEL OVERVIEW
- 17.145: ISRAEL OVERVIEW
- 17.146: LOCAL MARKET ANALYSIS - ISRAEL
- 17.147: COMPETITIVE ANALYSIS - ISRAEL
- 17.148: TURKEY OVERVIEW
- 17.149: TURKEY OVERVIEW
- 17.150: TURKEY OVERVIEW
- 17.151: TURKEY OVERVIEW
- 17.152: TURKEY OVERVIEW
- 17.153: TURKEY OVERVIEW
- 17.154: TURKEY OVERVIEW
- 17.155: TURKEY OVERVIEW
- 17.156: LOCAL MARKET ANALYSIS - TURKEY
- 17.157: COMPETITIVE ANALYSIS - TURKEY
- 17.158: REST OF EUROPE OVERVIEW
- 17.159: REST OF EUROPE OVERVIEW
- 17.160: REST OF EUROPE OVERVIEW
- 17.161: REST OF EUROPE OVERVIEW
- 17.162: REST OF EUROPE OVERVIEW
- 17.163: REST OF EUROPE OVERVIEW
- 17.164: REST OF EUROPE OVERVIEW
- 17.165: REST OF EUROPE OVERVIEW
- 17.166: LOCAL MARKET ANALYSIS - REST OF EUROPE
- 17.167: COMPETITIVE ANALYSIS - REST OF EUROPE
- 17.168: ASIA-PACIFIC OVERVIEW
- 17.169: ASIA-PACIFIC BY COUNTRY
- 17.170: CHINA OVERVIEW
- 17.171: CHINA OVERVIEW
- 17.172: CHINA OVERVIEW
- 17.173: CHINA OVERVIEW
- 17.174: CHINA OVERVIEW
- 17.175: CHINA OVERVIEW
- 17.176: CHINA OVERVIEW
- 17.177: CHINA OVERVIEW
- 17.178: LOCAL MARKET ANALYSIS - CHINA
- 17.179: COMPETITIVE ANALYSIS - CHINA
- 17.180: INDIA OVERVIEW
- 17.181: INDIA OVERVIEW
- 17.182: INDIA OVERVIEW
- 17.183: INDIA OVERVIEW
- 17.184: INDIA OVERVIEW
- 17.185: INDIA OVERVIEW
- 17.186: INDIA OVERVIEW
- 17.187: INDIA OVERVIEW
- 17.188: LOCAL MARKET ANALYSIS - INDIA
- 17.189: COMPETITIVE ANALYSIS - INDIA
- 17.190: JAPAN OVERVIEW
- 17.191: JAPAN OVERVIEW
- 17.192: JAPAN OVERVIEW
- 17.193: JAPAN OVERVIEW
- 17.194: JAPAN OVERVIEW
- 17.195: JAPAN OVERVIEW
- 17.196: JAPAN OVERVIEW
- 17.197: JAPAN OVERVIEW
- 17.198: LOCAL MARKET ANALYSIS - JAPAN
- 17.199: COMPETITIVE ANALYSIS - JAPAN
- 17.200: AUSTRALIA OVERVIEW
- 17.201: AUSTRALIA OVERVIEW
- 17.202: AUSTRALIA OVERVIEW
- 17.203: AUSTRALIA OVERVIEW
- 17.204: AUSTRALIA OVERVIEW
- 17.205: AUSTRALIA OVERVIEW
- 17.206: AUSTRALIA OVERVIEW
- 17.207: AUSTRALIA OVERVIEW
- 17.208: LOCAL MARKET ANALYSIS - AUSTRALIA
- 17.209: COMPETITIVE ANALYSIS - AUSTRALIA
- 17.210: INDONESIA OVERVIEW
- 17.211: INDONESIA OVERVIEW
- 17.212: INDONESIA OVERVIEW
- 17.213: INDONESIA OVERVIEW
- 17.214: INDONESIA OVERVIEW
- 17.215: INDONESIA OVERVIEW
- 17.216: INDONESIA OVERVIEW
- 17.217: INDONESIA OVERVIEW
- 17.218: LOCAL MARKET ANALYSIS - INDONESIA
- 17.219: COMPETITIVE ANALYSIS - INDONESIA
- 17.220: MALAYSIA OVERVIEW
- 17.221: MALAYSIA OVERVIEW
- 17.222: MALAYSIA OVERVIEW
- 17.223: MALAYSIA OVERVIEW
- 17.224: MALAYSIA OVERVIEW
- 17.225: MALAYSIA OVERVIEW
- 17.226: MALAYSIA OVERVIEW
- 17.227: MALAYSIA OVERVIEW
- 17.228: LOCAL MARKET ANALYSIS - MALAYSIA
- 17.229: COMPETITIVE ANALYSIS - MALAYSIA
- 17.230: REST OF APAC OVERVIEW
- 17.231: REST OF APAC OVERVIEW
- 17.232: REST OF APAC OVERVIEW
- 17.233: REST OF APAC OVERVIEW
- 17.234: REST OF APAC OVERVIEW
- 17.235: REST OF APAC OVERVIEW
- 17.236: REST OF APAC OVERVIEW
- 17.237: REST OF APAC OVERVIEW
- 17.238: LOCAL MARKET ANALYSIS - REST OF APAC
- 17.239: COMPETITIVE ANALYSIS - REST OF APAC
- 17.240: MIDDLE EAST AFRICA OVERVIEW
- 17.241: MIDDLE EAST AFRICA BY COUNTRY
- 17.242: SAUDI ARABIA OVERVIEW
- 17.243: SAUDI ARABIA OVERVIEW
- 17.244: SAUDI ARABIA OVERVIEW
- 17.245: SAUDI ARABIA OVERVIEW
- 17.246: SAUDI ARABIA OVERVIEW
- 17.247: SAUDI ARABIA OVERVIEW
- 17.248: SAUDI ARABIA OVERVIEW
- 17.249: SAUDI ARABIA OVERVIEW
- 17.250: LOCAL MARKET ANALYSIS - SAUDI ARABIA
- 17.251: COMPETITIVE ANALYSIS - SAUDI ARABIA
- 17.252: UAE OVERVIEW
- 17.253: UAE OVERVIEW
- 17.254: UAE OVERVIEW
- 17.255: UAE OVERVIEW
- 17.256: UAE OVERVIEW
- 17.257: UAE OVERVIEW
- 17.258: UAE OVERVIEW
- 17.259: UAE OVERVIEW
- 17.260: LOCAL MARKET ANALYSIS - UAE
- 17.261: COMPETITIVE ANALYSIS - UAE
- 17.262: SOUTH AFRICA OVERVIEW
- 17.263: SOUTH AFRICA OVERVIEW
- 17.264: SOUTH AFRICA OVERVIEW
- 17.265: SOUTH AFRICA OVERVIEW
- 17.266: SOUTH AFRICA OVERVIEW
- 17.267: SOUTH AFRICA OVERVIEW
- 17.268: SOUTH AFRICA OVERVIEW
- 17.269: SOUTH AFRICA OVERVIEW
- 17.270: LOCAL MARKET ANALYSIS - SOUTH AFRICA
- 17.271: COMPETITIVE ANALYSIS - SOUTH AFRICA
- 17.272: IRAN OVERVIEW
- 17.273: IRAN OVERVIEW
- 17.274: IRAN OVERVIEW
- 17.275: IRAN OVERVIEW
- 17.276: IRAN OVERVIEW
- 17.277: IRAN OVERVIEW
- 17.278: IRAN OVERVIEW
- 17.279: IRAN OVERVIEW
- 17.280: LOCAL MARKET ANALYSIS - IRAN
- 17.281: COMPETITIVE ANALYSIS - IRAN
- 17.282: QATAR OVERVIEW
- 17.283: QATAR OVERVIEW
- 17.284: QATAR OVERVIEW
- 17.285: QATAR OVERVIEW
- 17.286: QATAR OVERVIEW
- 17.287: QATAR OVERVIEW
- 17.288: QATAR OVERVIEW
- 17.289: QATAR OVERVIEW
- 17.290: LOCAL MARKET ANALYSIS - QATAR
- 17.291: COMPETITIVE ANALYSIS - QATAR
- 17.292: REST OF MEA OVERVIEW
- 17.293: REST OF MEA OVERVIEW
- 17.294: REST OF MEA OVERVIEW
- 17.295: REST OF MEA OVERVIEW
- 17.296: REST OF MEA OVERVIEW
- 17.297: REST OF MEA OVERVIEW
- 17.298: REST OF MEA OVERVIEW
- 17.299: REST OF MEA OVERVIEW
- 17.300: LOCAL MARKET ANALYSIS - REST OF MEA
- 17.301: COMPETITIVE ANALYSIS - REST OF MEA
- 18.0: COMPETITION OVERVIEW
- 18.1: MARKET SHARE ANALYSIS
- 18.2: MARKET REVENUE BY KEY COMPANIES
- 18.3: MARKET POSITIONING
- 18.4: VENDORS BENCHMARKING
- 18.5: STRATEGY BENCHMARKING
- 18.6: STRATEGY BENCHMARKING
- 19.0: Gilead Sciences
- 19.1: Gilead Sciences
- 19.2: Gilead Sciences
- 19.3: Gilead Sciences
- 19.4: Gilead Sciences
- 19.5: Novartis
- 19.6: Novartis
- 19.7: Novartis
- 19.8: Novartis
- 19.9: Novartis
- 19.10: Bristol Myers Squibb
- 19.11: Bristol Myers Squibb
- 19.12: Bristol Myers Squibb
- 19.13: Bristol Myers Squibb
- 19.14: Bristol Myers Squibb
- 19.15: Amgen
- 19.16: Amgen
- 19.17: Amgen
- 19.18: Amgen
- 19.19: Amgen
- 19.20: Regeneron Pharmaceuticals
- 19.21: Regeneron Pharmaceuticals
- 19.22: Regeneron Pharmaceuticals
- 19.23: Regeneron Pharmaceuticals
- 19.24: Regeneron Pharmaceuticals
- 19.25: Bluebird Bio
- 19.26: Bluebird Bio
- 19.27: Bluebird Bio
- 19.28: Bluebird Bio
- 19.29: Bluebird Bio
- 19.30: CRISPR Therapeutics
- 19.31: CRISPR Therapeutics
- 19.32: CRISPR Therapeutics
- 19.33: CRISPR Therapeutics
- 19.34: CRISPR Therapeutics
- 19.35: Celgene Corporation
- 19.36: Celgene Corporation
- 19.37: Celgene Corporation
- 19.38: Celgene Corporation
- 19.39: Celgene Corporation
- 19.40: Kite Pharma
- 19.41: Kite Pharma
- 19.42: Kite Pharma
- 19.43: Kite Pharma
- 19.44: Kite Pharma
- 19.45: Juno Therapeutics
- 19.46: Juno Therapeutics
- 19.47: Juno Therapeutics
- 19.48: Juno Therapeutics
- 19.49: Juno Therapeutics
- 19.50: Vericel Corporation
- 19.51: Vericel Corporation
- 19.52: Vericel Corporation
- 19.53: Vericel Corporation
- 19.54: Vericel Corporation
- 19.55: Fate Therapeutics
- 19.56: Fate Therapeutics
- 19.57: Fate Therapeutics
- 19.58: Fate Therapeutics
- 19.59: Fate Therapeutics
- 19.60: Spark Therapeutics
- 19.61: Spark Therapeutics
- 19.62: Spark Therapeutics
- 19.63: Spark Therapeutics
- 19.64: Spark Therapeutics
- 19.65: Humanigen
- 19.66: Humanigen
- 19.67: Humanigen
- 19.68: Humanigen
- 19.69: Humanigen
- 19.70: Poseida Therapeutics
- 19.71: Poseida Therapeutics
- 19.72: Poseida Therapeutics
- 19.73: Poseida Therapeutics
- 19.74: Poseida Therapeutics
- 19.75: Sangamo Therapeutics
- 19.76: Sangamo Therapeutics
- 19.77: Sangamo Therapeutics
- 19.78: Sangamo Therapeutics
- 19.79: Sangamo Therapeutics
- 19.80: Orchard Therapeutics
- 19.81: Orchard Therapeutics
- 19.82: Orchard Therapeutics
- 19.83: Orchard Therapeutics
- 19.84: Orchard Therapeutics
- 19.85: Adaptimmune Therapeutics
- 19.86: Adaptimmune Therapeutics
- 19.87: Adaptimmune Therapeutics
- 19.88: Adaptimmune Therapeutics
- 19.89: Adaptimmune Therapeutics
- 19.90: Nkarta Therapeutics
- 19.91: Nkarta Therapeutics
- 19.92: Nkarta Therapeutics
- 19.93: Nkarta Therapeutics
- 19.94: Nkarta Therapeutics
- 19.95: Allogene Therapeutics
- 19.96: Allogene Therapeutics
- 19.97: Allogene Therapeutics
- 19.98: Allogene Therapeutics
- 19.99: Allogene Therapeutics
- 611})
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.